Stanton R. Mehr

Among the articles provided in this issue are topics presented at the 43rd annual meeting of the American Society of Clinical Oncology: 1) Spain: When Two "Mabs" Are Better Than One 2) United Kingdom: Evidence Mounts Against Use of Adjuvant External Beam Radiotherapy in Endometrial Cancer 3) Norway: Clinical Data Suggest Potential Versatility of Pemetrexed for Injection (Alimta)-Based Regimens in Lung Cancer 4) Germany: An Anti-Inflammatory Approach to Inducing Remission in Metastatic Prostate Cancer

Phase IV:1) Cancer Risks and Postmenopausal Hormone Link ConfirmedPhase III:1) Do Vitamins Protect Against Lung Cancer?2) Longer Life Expectancy in Pancreatic Cancer When Gemcitabine Is Added to Chemotherapy3) Outcomes Improve With Letrozole Treatment in Women With Early-Stage Breast Cancer4. Pemetrexed vs. Docetaxel for Non-Small Cell Lung Cancer TreatmentPhase II:1) Talactoferrin-Alfa Treatment for Non-Small Cell Lung Cancer2) Advanced Carcinoid Systemic Therapy

Using a database of managed care claims, outcomes researchers at Huffman-La Roche Inc in Nutley, New Jersey, examined the total cost of care for patients with metastatic colorectal cancer (N = 1459) who received 5-fluorouracil (5-FU)-based regimens or capecitabine-based chemotherapy regimens from 2004-2006.

Although imatinib mesylate (Gleevec) is the standard of care for patients with metastatic or unresectable gastrointestinal stromal tumors (GIST), few studies have examined its cost-effectiveness in treating this disorder.